Manesh Patel, MD: New Therapies for Cardiovascular Risk Management

July 7, 2021
Connor Iapoce

Connor Iapoce is an assistant editor for HCPLive and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at ciapoce@mjhlifesciences.com.

Dr. Manesh Patel shares perspective on the "renaissance of anti-thrombotic therapy" for patients at risk of cardiovascular events.

In an interview with HCPLive®, Manesh Patel, MD, Duke University School of Medicine recapped a recent discussion on treatment of patients at-risk of cardiovascular (CV) events.

Patel was the chair of the HCPLive® State of the Science "Institutional Perspectives in Cardiology: Cardiovascular Risk Management" expert webinar.

Patel introduced the event and presented a talk called "Putting This All Together: Treatment Pyramid," in which he discussed his strategy on how to think about which drug to use for patients with thromboembolic disease, as well as atherothrombosis.

"I sort of think about indications in the way we take care of our patients with the highest indication being either atrial fibrillation (AF) stroke prevention or venous thromboembolism (VTE) treatment," Patel said. "The second indication in the pyramid or sort of one rung down lower is VTE prevention. Then, the bottom base for most patients that have coronary and vascular disease is atherothrombotic prevention."

Patel also noted the case based discussions highlighted by Christopher Granger, MD and Schuyler Jones, MD, regarding atrial fibrillation and CAD/PAD risk, respectively.

He further highlighted his thoughts on how to use new therapies, including PCSK9 inhibitors and future research into reducing cardiovascular events and improving CV health.

"I think institutional perspectives are always interesting because they speak to what people know and obviously there's things we don't know," Patel said. "What you learn is that the care pathways, the available evidence we have and how we apply to the patients in front of us, and the institutional perspectives we discussed were somewhat unique to Duke, but certainly spoke a lot about challenges we all face in caring for our patients with a broad vascular disease or thromboembolic disease or prevention of atrial fibrillation."


x